Pay in 4 interest-free payments of $7.15 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
Renoprotective effects of combination treatment with sodium-glucose cotransporter inhibitors and GLP-1 receptor agonists in patients with type 2 diabetes mellitus according to preceding medication
Room temperature medication flows more easily, distributes more evenly through the subcutaneous tissue, and absorbs more quickly
These data reinforce the potential clinical benefits of long-term therapy for people living with obesity and pre-diabetes. SURMOUNT-1 (NCT04184622) was a multi-center, randomized, double-blind, parallel, placebo-controlled trial comparing 5 mg, 10 mg, and 15 mg of tirzepatide to placebo as an adjunct to a reduced-calorie diet and increased physical activity in adults with pre-diabetes and obesity or overweight with at least 1 of the following comorbidities: hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease
Trials (2017) 18:255
US$ 24.49
US$ 27.53
US$ 29.87
US$ 20.27
US$ 21.53
